OR WAIT null SECS
Catalent will expand primary packaging capabilities and commission an automated, high-speed bottling line for clinical packaging of capsules and tablets.
Catalent Pharma Solutions announced in a Nov. 27, 2018 press release that work to expand its primary packaging capabilities at its clinical facility in Shanghai, China has reached the commissioning stage and is scheduled to be completed by the end of 2018.
The expansion includes a new automated, high-speed bottling line suitable for capsule and tablet products. The line will increase packaging capacity by up to 100 bottles per minute and provide for quick and easy changeover, which is essential for clinical-scale production.
“Our continued investment in Asia Pacific reflects the importance of, and the continued growth of clinical trials in Asia, driving the need for in-region packaging services,” said Roel de Nobel, Catalent’s vice-president, Global Operations, Clinical Supply Services, in the press release.
This expansion follows the announcement that work is underway to open a new clinical facility outside of Shanghai’s free trade zone (FTZ). The new facility is expected to be completed in early 2019 and will join the company’s existing three clinical packaging facilities in the Asia Pacific region, namely in Shanghai’s Waigaoqiao FTZ; Singapore; and Kakegawa, Japan. In addition to its primary packaging capabilities, the company offers comprehensive clinical supply solutions in the region including clinical supply management, comparator sourcing, FastChain demand-led supply, secondary packaging, storage and global distribution, and clinical returns and destruction.